The parallel distributor has informed its supplied customers in a letter dated 18.04.2014 that Herceptin in Italian presentation has been adulterated and introduced into the legal distribution chain. Therefore, a recall of the above mentioned Italian batches, which were marketed in parallel distribution in Austria, will now be carried out.

Update from the European Medicines Agency on stolen vials of Herceptin and other affected products

The distribution company informed its supplied customers on17.04.2014 and asked for a stock check of the affected batch.

The parallel distributor informed its supplied customers on 04/17/2014 and asked for a stock check of the affected batches.

The parallel distributor informed its supplied customers in a letter dated April 17, 2014, that Alimta in Italian presentation is being recalled as a precautionary measure, as it cannot be ensured that the regular distribution chain has been adhered to.

The European Medicines Agency received information that vials of Herceptin, a drug used to treat cancer, were adulterated and introduced into the legal distribution chain.

The parallel distributor has informed its supplied customers in a letter dated 16.04.2014 that Herceptin in Italian presentation has been adulterated and introduced into the legal distribution chain. Therefore, a recall of the above mentioned Italian batches, which were marketed in parallel distribution in Austria, will now be carried out.

The distribution company informed its supplied customers on 04/16/2014 and asked for a stock check of the affected batch.

The marketing authorization holder has informed its wholesalers in a letter dated April 11, 2014, that the contract manufacturer for "Paroxetine-ratiopharm 20 mg Film-Coated Tablets" has received a "Warning letter" from the FDA (US Food and Drug Administration) with concerns regarding the release of the active ingredient "Paroxetine". This affects…

The marketing authorization holder informed its wholesalers in a letter dated April 10, 2014, that GlaxoSmithKline (GSK) had received a warning letter from the FDA (US Food and Drug Administration) with concerns about the release of the active ingredient paroxetine. Batches of the active ingredient produced at GSK's Cork, Ireland facility between…